Questcor shareholders are left picking up the pieces after shares were nearly halved on Wednesday. The drop followed a clinical policy bulletin from insurer Aetna outlining a change in coverage policies for Questcor's flagship drug Acthar.
In an article written shortly after the news, Brenton said that shareholders had a right to be concerned about this issue, particularly the risk that more insurers would follow suit. After all, even though Aetna accounts for only around 5% of paid prescriptions of Acthar, its update largely excludes multiple sclerosis -- by far the most important indication for the drug -- from coverage going forward. If more insurers were to jump on the bandwagon, Acthar shipments could take a cliff dive.
However, Brenton feels slightly more comfortable after listening in on a call hosted by Questcor on Thursday morning. It's never bad to be skeptical of pronouncements from company managements, but in this case there were some valuable details on the dynamics at work with this drug, particularly in the MS indication.
In the following video, Brenton dives into some of that detail, as well as an interesting disclosure Questcor provides on its annual report that could have raised warning flags for investors.
Attention to the small details in annual reports can oftentimes prove the difference-maker between buying a market laggard and a stock with true multibagger potential. It's just one tool you can use in your quest to build long-term wealth and retire well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some more winning wealth-building strategies. Click here to claim your copy now.
Brenton Flynn and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.